Skip to main content

Table 3 Adverse events reported in each group

From: The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

  Placebo (%) MPD (%) Total
Insomnia, Anxiety/Nervousness 2 (16,67) 11 (37,93) 13
Headache 3 (25,00) 3 (10,34) 6
Anorexia/Decreased appetite 0 (0,00) 6 (20,69) 6
Abdominal pain 2 (16,67) 2 (6,90) 4
Abnormal loss of weight 1 (8,33) 1 (3,45) 2
Vomiting/Nausea 0 (0,00) 2 (6,90) 2
Other* 4 (33,33) 4 (13,79) 8
Total 12 29 41
  1. *Tonsillitis, dysphemia, hot flush, enuresis, asthenia, attention deficit, rash.